Pre-qualify to use GLP-1s for craving reduction
We aim to help people face two of the greatest epidemics in America: obesity and addiction.
Peer-reviewed research studies indicate that GLP-1 medications may be more effective than several existing medications for harm reduction, reducing cravings for alcohol, drugs, and nicotine.
Several of our team members are recovered alcoholics, and a number of the life coaches our clients work with have lived experience in recovery. We have resources in Los Angeles and across the country for addiction treatment, from sober living houses to detox, inpatient and outpatient programs, as well as interventionists and sober companions.
We work with individuals and with businesses to give their clients the best possible outcomes. Call or text us anytime if you’re struggling: 424-902-0025
The published evidence
Heavy drinking reductions
First-ever clinical trial showing large reductions in high-risk heavy drinking.
Alcohol and opioid outcomes
Reported 50% lower rate of alcohol bingeing and 40% lower rate of opioid overdose among those prescribed these medications.
The broader case
Medical evidence for opioid, nicotine, and alcohol use disorder.
Research links are provided for information only and do not constitute medical advice or a claim about individual outcomes.
See if this is a fit
Individual results vary. Testimonials reflect individual experiences and are not a guarantee of outcome. Peptide therapies are prescribed only after a medical consultation and are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the Food and Drug Administration.